Multiple myeloma and cardiovascular risk (a literature review)
Multiple myeloma is a plasma cell clonal malignancy that accounts for 10 % of hematological cancers. It predominantly affects elderly people; median age at diagnosis is 70 years. Consequently, many patients with MM have cardiovascular comorbidities or risk factors. MM can cause cardiac comorbidities...
Saved in:
Main Authors: | B. B. Samura (Author), M. O. Panasenko (Author), S. Ya. Dotsenko (Author) |
---|---|
Format: | Book |
Published: |
Zaporozhye State Medical University,
2020-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Value of P-selectin in the prognosis of cardiovascular events in patients with multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022) -
Circulating sST2 and prognosis of cardiovascular events in remission of multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022) -
Prognostic value of P-selectin and sST2 in patients with multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022) -
Cardiovascular events after polychemotherapy of multiple myeloma: modern ways to diagnostics
by: B. B. Samura, et al.
Published: (2020) -
Cariohemodynamics in patients with multiple myeloma depending on renal function
by: B. B. Samura, et al.
Published: (2019)